Opportunistic viral infections in intestinal transplantation

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 4, 2013, Pages 367-381

  Florescu, Diana F ^a,b   Langnas, Alan N ^b   Sandkovsky, Uriel ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

adenovirus; cytomegalovirus; intestinal; intestinal transplantation; small bowel; transplantation; viral infections

Indexed keywords

ACICLOVIR; ALN RSV 01; AMANTADINE; CHICKENPOX VACCINE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOSPORIN; EVEROLIMUS; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; LETERMOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITAZOXANIDE; OSELTAMIVIR; PALIVIZUMAB; PLACEBO; PROBENECID; RIBAVIRIN; RIMANTADINE; RITUXIMAB; ROTAVIRUS VACCINE; TACROLIMUS; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE; ZANAMIVIR;

ADENOVIRUS INFECTION; APNEA; ATELECTASIS; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHICKENPOX; CONJUNCTIVITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; ELECTROLYTE DISTURBANCE; EPSTEIN BARR VIRUS INFECTION; FLUID THERAPY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN METAPNEUMOVIRUS INFECTION; INFECTION RISK; INFLUENZA; INTESTINAL FAILURE; INTESTINE TRANSPLANTATION; KIDNEY DYSFUNCTION; LABORATORY TEST; LACRIMATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NOROVIRUS INFECTION; OPPORTUNISTIC INFECTION; PARAINFLUENZA VIRUS INFECTION; PARENTERAL NUTRITION; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RISK REDUCTION; ROTAVIRUS INFECTION; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS INFECTION; VIRUS PNEUMONIA; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTESTINES; MALE; OPPORTUNISTIC INFECTIONS; PARENTERAL NUTRITION; SURVIVAL ANALYSIS; TISSUE TRANSPLANTATION; VIRUS DISEASES;

EID: 84879958077     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.13.25     Document Type: Review

References (162)

1. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am. J. Transplant. 12(Suppl. 1), 1-156 (2012).
2. Langnas A, Chinnakotla S, Sudan D et al. Intestinal transplantation at the University of Nebraska Medical Center: 1990 to 2001. Transplant. Proc. 34(3), 958-960 (2002).
3. Nishida S, Levi D, Kato T et al. Ninety-five cases of intestinal transplantation at the University of Miami. J. Gastrointest. Surg. 6(2), 233-239 (2002).
4. Sauvat F, Dupic L, Caldari D et al. Factors influencing outcome after intestinal transplantation in children. Transplant. Proc. 38(6), 1689-1691 (2006).
5. Todo S, Reyes J, Furukawa H et al. Outcome analysis of 71 clinical intestinal transplantations. Ann. Surg. 222(3), 270-280; discussion 280 (1995).
6. Abu-Elmagd KM, Costa G, Bond GJ et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann. Surg. 250(4), 567-581 (2009).
7. Florescu DF, Langnas AN, Grant W et al. Incidence, risk factors, and outcomes associated with cytomegalovirus disease in small bowel transplant recipients. Pediatr. Transplant. 16(3), 294-301 (2012).
8. Munoz MA, Andrés A, Gallego R et al. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant. Proc. 34(1), 97 (2002).
9. Guaraldi G, Cocchi S, Codeluppi M et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 80(12), 1742-1748 (2005).
10. Lauro A, Di Benedetto F, Masetti M et al. Twenty-seven consecutive intestinal and multivisceral transplants in adult patients: a 4-year clinical experience. Transplant. Proc. 37(6), 2679-2681 (2005).
11. Bueno J, Green M, Kocoshis S et al. Cytomegalovirus infection after intestinal transplantation in children. Clin. Infect. Dis. 25(5), 1078-1083 (1997).
12. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S78-S86 (2009). 13. Kalil AC, Florescu DF, Sun J. Induction Immunosuppression: what is the difference in the risk of serious infections between interleukin-2RA and polyclonal antibodies? Am. J. Transplant. 9(Suppl. s2), 283 (2009) (Abstract 317).
13. Adams AB, Larsen CP, Pearson TC, Newell KA. The role of TNF receptor and TNF superfamily molecules in organ transplantation. Am. J. Transplant. 2(1), 12-18 (2002).
14. Chapenko S, Folkmane I, Tomsone V, Amerika D, Rozentals R, Murovska M. Co-infection of two beta-herpesviruses (CMV and HHV-7) as an increased risk factor for 'CMV disease' in patients undergoing renal transplantation. Clin. Transplant. 14(5), 486-492 (2000).
15. Härmä M, Höckerstedt K, Lyytikäinen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J. Med. Virol. 78(6), 800-805 (2006).
16. Lautenschlager I, Linnavuori K, Lappalainen M, Suni J, Höckerstedt K. HHV-6 reactivation is often associated with CMV infection in liver transplant patients. Transpl. Int. 13(Suppl. 1), S351-S353 (2000).
17. Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am. J. Transplant. 13(Suppl. 3), 67-78 (2013).
18. Paya C, Humar A, Dominguez E et al.; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
19. Mañez R, Kusne S, Green M et al. Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation 59(7), 1010-1014 (1995).
20. Iwaki Y, Starzl TE, Yagihashi A et al. Replacement of donor lymphoid tissue in small-bowel transplants. Lancet 337(8745), 818-819 (1991).
21. Paya CV, Razonable RR. Cytomegalovirus infections after solid organ transplantation. In: Transplant Infections. Bowden RA, Ljungman P, Paya CV (Eds). Lippincott Williams & Wilkins, PA, USA, 298-325 (2003).
22. Roche JK, Cheung KS, Boldogh I, Huang ES, Lang DJ. Cytomegalovirus: detection in human colonic and circulating mononuclear cells in association with gastrointestinal disease. Int. J. Cancer 27(5), 659-667 (1981).
23. Florescu DF, Kalil AC. Cytomegalovirus infections in nonimmunocompromised and immunocompromised patients in the intensive care unit. Infect. Disord. Drug Targets 11(4), 354-364 (2011).
24. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S. Association of renal allograft rejection with virus infections. Am. J. Med. 56(3), 280-289 (1974).
25. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr. Opin. Infect. Dis. 20(4), 399-407 (2007).
26. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am. J. Transplant. 9(11), 2453-2458 (2009).
27. Lugert R, Reichard U, Hufert FT, Gross U. Comparison between pp65 antigenemia assay and quantitative real-time polymerase chain reaction for detection of active cytomegalovirus infection in routine diagnostics. Diagn. Microbiol. Infect. Dis. 65(2), 192-195 (2009).
28. Camargo LF, Uip DE, Simpson AA et al. Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation. Transplantation 71(3), 412-417 (2001).
29. Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 71(11), 1609-1615 (2001).
30. Gimeno C, Solano C, Latorre JC et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of pre-emptive therapy for allogeneic hematopoietic stem cell transplant recipients. J. Clin. Microbiol. 46(10), 3311-3318 (2008).
31. Meyer-Koenig U, Romberg I, Schneider K, Weidmann M, Kern WV, Hufert FT. Diagnostic value of reverse transcription-PCR for detection of cytomegalovirus pp67 in samples from solid-organ transplant recipients. J. Clin. Microbiol. 44(9), 3394-3396 (2006).
32. Sanghavi SK, Abu-Elmagd K, Keightley MC et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J. Clin. Virol. 42(4), 335-342 (2008).
33. Tanaka N, Kimura H, Iida K et al. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J. Med. Virol. 60(4), 455-462 (2000).
34. Kotton CN. CMV: Prevention, diagnosis and therapy. Am. J. Transplant. 13(Suppl. 3), 24-40 (2013).
35. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK; American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 9(2), 258-268 (2009).
36. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin. Infect. Dis. 54(12), 1793-1797 (2012).
37. Jiwa NM, Raap AK, van de Rijke FM et al. Detection of cytomegalovirus antigens and DNA in tissues fixed in formaldehyde. J. Clin. Pathol. 42(7), 749-754 (1989).
38. Naoumov NV, Alexander GJ, O'Grady JG et al. Rapid diagnosis of cytomegalovirus infection by in-situ hybridisation in liver grafts. Lancet 1(8599), 1361-1364 (1988).
39. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin. Transplant. 22(1), 89-97 (2008).
40. Kaplan CS, Petersen EA, Icenogle TB et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch. Intern. Med. 149(9), 2095-2100 (1989).
41. Mayoral JL, Loeffler CM, Fasola CG et al. Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. Arch. Surg. 126(2), 202-206 (1991).
42. Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109(10), 777-782 (1988).
43. Ljungman P, Engelhard D, Link H et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin. Infect. Dis. 14(4), 831-835 (1992).
44. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109(10), 783-788 (1988).
45. Schmidt GM, Kovacs A, Zaia JA et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 46(6), 905-907 (1988).
46. Robertson J, Elidemir O, Saz EU et al. Hypogammaglobulinemia: Incidence, risk factors, and outcomes following pediatric lung transplantation. Pediatr. Transplant. 13(6), 754-759 (2009).
47. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J. Heart Lung Transplant. 26(12), 1286-1292 (2007).
48. Chou S, Erice A, Jordan MC et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171(3), 576-583 (1995).
49. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172(1), 239-242 (1995).
50. Sullivan V, Biron KK, Talarico C et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonyl-methoxyalkyl derivatives. Antimicrob. Agents Chemother. 37(1), 19-25 (1993).
51. Bravo FJ, Bernstein DI, Beadle JR, Hostetler KY, Cardin RD. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob. Agents Chemother. 55(1), 35-41 (2011).
52. Marty FM, Winston D, Rowley SD et al. CMX001 for prevention and control of CMV infection in CMV-seropositive allogeneic stem-cell transplant recipients: a Phase II randomized, double-blind, placebo-controlled, dose-escalation trial of safety, tolerability and antiviral activity. Biol. Blood Marrow Transplant. 18(Suppl. 2), S203-S204 (2012).
53. Shroff R, Rees L. The post-transplant lymphoproliferative disorder - a literature review. Pediatr. Nephrol. 19(4), 369-377 (2004).
54. Allen U, Preiksaitis J; AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S87-S96 (2009).
55. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl. Int. 20(3), 207-218 (2007).
56. Green M, Bueno J, Rowe D et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70(4), 593-596 (2000).
57. Pascher A, Klupp J, Schulz RJ, Dignass A, Neuhaus P. CMV, EBV, HHV-6, and HHV-7 infections after intestinal transplantation without specific antiviral prophylaxis. Transplant. Proc. 36(2), 381-382 (2004).
58. Nalesnik M, Jaffe R, Reyes J et al. Posttransplant lymphoproliferative disorders in small bowel allograft recipients. Transplant. Proc. 32(6), 1213 (2000).
59. Quintini C, Kato T, Gaynor JJ et al. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplant. Proc. 38(6), 1755-1758 (2006).
60. Reyes J, Green M, Bueno J et al. Epstein Barr virus associated posttransplant lymphoproliferative disease after intestinal transplantation. Transplant. Proc. 28(5), 2768-2769 (1996).
61. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 56(1), 29-44 (2005).
62. Allen UD, Farkas G, Hébert D et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr. Transplant. 9(4), 450-455 (2005).
63. Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am. J. Pathol. 147(6), 1862-1870 (1995).
64. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am. J. Clin. Pathol. 103(6), 748-755 (1995).
65. Bakker NA, van Imhoff GW. Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica 92(11), 1447-1450 (2007).
66. Faye A, Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr. Drugs 7(1), 55-65 (2005).
67. Ghobrial IM, Habermann TM, Macon WR et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 79(2), 244-247 (2005).
68. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4(2), 222-230 (2004).
69. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann. Pharmacother. 41(11), 1850-1858 (2007).
70. Preiksaitis JK, Cockfield SM. Epstein-Barr virus infection and lymphoprolipherative disorders after transplantation. In: Transplant Infections (3rd Edition). Bowden RA, Ljungman P, Snydman DR (Eds). Wolters Kluwer Health/Lippincott Williams & Wilkins, PA, USA, 362-390 (2010).
71. Baldanti F, Grossi P, Furione M et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J. Clin. Microbiol. 38(2), 613-619 (2000).
72. Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68(10), 1517-1525 (1999).
73. Green M, Michaels MG, Webber SA, Rowe D, Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr. Transplant. 3(4), 271-281 (1999).
74. Abu-Elmagd KM, Mazariegos G, Costa G et al. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation 88(7), 926-934 (2009).
75. Allen U, Hebert D, Petric M et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin. Infect. Dis. 33(2), 145-150 (2001).
76. Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG; American Society of Transplantation Infectious Diseases Community of Practice. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am. J. Transplant. 9(2), 269-279 (2009).
77. Humar A, Hébert D, Davies HD et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81(6), 856-861 (2006).
78. Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using pre-emptive antiviral therapy. Transplantation 64(6), 848-852 (1997).
79. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylaxis and the Epstein Barr virusrelated post-transplant lymphoproliferative disorder. Clin. Transplant. 9(1), 53-59 (1995).
80. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant. 5(12), 2894-2900 (2005).
81. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am. J. Transplant. 13(Suppl. 3), 41-54 (2013).
82. Mazariegos GV. Intestinal transplantation: current outcomes and opportunities. Curr. Opin. Organ Transplant. 14(5), 515-521 (2009).
83. Green MBJ, Sigurdsson L, Mazariegos G, Abu-Elmagd K, Reyes J. Unique aspects of the infectious complications of intestinal transplantation. Curr. Opin. Organ Transplant. 4(4), 361-367 (1999).
84. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter Phase II study. Blood 107(8), 3053-3057 (2006).
85. González-Barca E, Domingo-Domenech E, Capote FJ et al.; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas). Prospective Phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 92(11), 1489-1494 (2007).
86. Oertel SH, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am. J. Transplant. 5(12), 2901-2906 (2005).
87. Gross TG, Bucuvalas JC, Park JR et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J. Clin. Oncol. 23(27), 6481-6488 (2005).
88. Dharnidharka VR, Gupta S. PTLD treatment: reducing the chemotherapy burden through addition of rituximab. Pediatr. Transplant. 14(1), 10-11 (2010).
89. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am. J. Transplant. 6(3), 569-576 (2006).
90. Gross TG, Orjuela MA, Perkins SL et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am. J. Transplant. 12(11), 3069-3075 (2012).
91. Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann. Pharmacother. 41(10), 1648-1659 (2007).
92. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N. Engl. J. Med. 347(5), 340-346 (2002).
93. Heininger U, Seward JF. Varicella. Lancet 368(9544), 1365-1376 (2006).
94. Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 90(2 Pt 1), 216-220 (1992).
95. McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC Jr. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 83(2), 256-261 (1989).
96. Pergam SA, Limaye AP; AST Infectious Diseases Community of Practice. Varicella zoster virus (VZV) in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S108-S115 (2009).
97. Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am. J. Transplant. 7(4), 741-747 (2007).
98. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am. J. Transplant. 4(1), 108-115 (2004).
99. Gnann JW Jr. Herpes simplex and varicella-zoster virus infection after hematopoietic stem cell or solid organ transplantation. In: Transplant infections (3rd Edition). Bowden RA, Ljungman PS, David R (Eds). Wolters Kluwer Health/ Lippincott Williams & Wilkins, PA, USA, 391-410 (2010).
100. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV; PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. Infect. Dis. 192(8), 1331-1339 (2005).
101. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs 64(24), 2763-2792 (2004).
102. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule - United States, 2013. Pediatrics 131(2), 397-398 (2013).
103. Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am. J. Transplant. 13(Suppl. 3), 55-66 (2013).
104. Danzinger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 9(Suppl. 4), S258-S262 (2009).
105. Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch. Dermatol. 142(7), 943-945 (2006).
106. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 347(1), 26-34 (2002).
107. Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr. Transplant. 10(1), 78-82 (2006).
108. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team. Administration of live varicella vaccine to HIVinfected children with current or past significant depression of CD4(+) T cells. J. Infect. Dis. 194(2), 247-255 (2006).
109. Weinberg A, Horslen SP, Kaufman SS et al. Safety and immunogenicity of varicellazoster virus vaccine in pediatric liver and intestine transplant recipients. Am. J. Transplant. 6(3), 565-568 (2006).
110. Posfay-Barbe KM, Pittet LF, Sottas C et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am. J. Transplant. 12(11), 2974-2985 (2012).
111. Tunbäck P, Bergström T, Claesson BA, Carlsson RM, Löwhagen GB. Early acquisition of herpes simplex virus type 1 antibodies in children - a longitudinal serological study. J. Clin. Virol. 40(1), 26-30 (2007).
112. Xu F, Sternberg MR, Kottiri BJ et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296(8), 964-973 (2006).
113. Razonable RR. Management of viral infections in solid organ transplant recipients. Expert Rev. Anti Infect. Ther. 9(6), 685-700 (2011).
114. Zuckerman R, Wald A; AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S104-S107 (2009).
115. Delis S, Kato T, Ruiz P, Mittal N, Babinski L, Tzakis A. Herpes simplex colitis in a child with combined liver and small bowel transplant. Pediatr. Transplant. 5(5), 374-377 (2001).
116. Razonable RR, Zerr DM; AST Infectious Diseases Community of Practice. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S97-S100 (2009).
117. Carratalà J, Montejo M, Pérez-Romero P. Infections caused by herpes viruses other than cytomegalovirus in solid organ transplant recipients. Enferm. Infecc. Microbiol. Clin. 30(Suppl. 2), 63-69 (2012).
118. Petrisli E, Chiereghin A, Gabrielli L et al. Early and late virological monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients. Transplant. Proc. 42(1), 74-78 (2010).
119. Singh N. Infections with human herpesvirus- 6, -7, and -8 after hematopoietic stem cell or solid organ transplantation. In: Transplant infections (3rd Edition). Bowden RA, Ljungman PS, David R (Eds). Wolters Kluwer Health/Lippincott Williams & Wilkins, PA, USA, 411-420 (2010).
120. Florescu DF, Islam MK, Mercer DF et al. Adenovirus infections in pediatric small bowel transplant recipients. Transplantation 90(2), 198-204 (2010).
121. McLaughlin GE, Delis S, Kashimawo L et al. Adenovirus infection in pediatric liver and intestinal transplant recipients: utility of DNA detection by PCR. Am. J. Transplant. 3(2), 224-228 (2003).
122. Parizhskaya M, Walpusk J, Mazariegos G, Jaffe R. Enteric adenovirus infection in pediatric small bowel transplant recipients. Pediatr. Dev. Pathol. 4(2), 122-128 (2001).
123. Pinchoff RJ, Kaufman SS, Magid MS et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 76(1), 183-189 (2003).
124. Ziring D, Tran R, Edelstein S et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation 79(6), 702-709 (2005).
125. Hoffman JA. Adenoviral disease in pediatric solid organ transplant recipients. Pediatr. Transplant. 10(1), 17-25 (2006).
126. Berho M, Torroella M, Viciana A et al. Adenovirus enterocolitis in human small bowel transplants. Pediatr. Transplant. 2(4), 277-282 (1998).
127. Gabriel R, Selwyn S, Brown D et al. Virus infections and acute renal transplant rejection. Nephron 16(4), 282-286 (1976).
128. Shirali GS, Ni J, Chinnock RE et al. Association of viral genome with graft loss in children after cardiac transplantation. N. Engl. J. Med. 344(20), 1498-1503 (2001).
129. Echavarría M. Adenoviruses in immunocompromised hosts. Clin. Microbiol. Rev. 21(4), 704-715 (2008).
130. Ison MG, Green M; AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S161-S165 (2009).
131. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7(7), 388-394 (2001).
132. Seidemann K, Heim A, Pfister ED et al. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am. J. Transplant. 4(12), 2102-2108 (2004).
133. Florescu DF, Pergam SA, Neely MN, Qiu F et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol. Blood Marrow Transplant. 18(5), 731-738 (2012).
134. Humar A, Kumar D, Mazzulli T et al.; PV16000 Study Group. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am. J. Transplant. 5(10), 2555-2559 (2005).
135. Adeyi OA, Costa G, Abu-Elmagd KM, Wu T. Rotavirus infection in adult small intestine allografts: a clinicopathological study of a cohort of 23 patients. Am. J. Transplant. 10(12), 2683-2689 (2010).
136. Fischer TK, Viboud C, Parashar U et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. J. Infect. Dis. 195(8), 1117-1125 (2007).
137. Eisengart LJ, Chou PM, Iyer K, Cohran V, Rajaram V. Rotavirus infection in small bowel transplant: a histologic comparison with acute cellular rejection. Pediatr. Dev. Pathol. 12(2), 85-88 (2009).
138. Florescu DF, Hermsen ED, Kwon JY et al. Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients? Pediatr. Transplant. 15(7), 718-721 (2011).
139. Kaufman SS, Chatterjee NK, Fuschino ME et al. Characteristics of human calicivirus enteritis in intestinal transplant recipients. J. Pediatr. Gastroenterol. Nutr. 40(3), 328-333 (2005).
140. Saif MA, Bonney DK, Bigger B et al. Chronic norovirus infection in pediatric hematopoietic stem cell transplant recipients: a cause of prolonged intestinal failure requiring intensive nutritional support. Pediatr. Transplant. 15(5), 505-509 (2011).
141. Moe CL, Gentsch J, Ando T et al. Application of PCR to detect Norwalk virus in fecal specimens from outbreaks of gastroenteritis. J. Clin. Microbiol. 32(3), 642-648 (1994).
142. Schwab KJ, Estes MK, Neill FH, Atmar RL. Use of heat release and an internal RNA standard control in reverse transcription-PCR detection of Norwalk virus from stool samples. J. Clin. Microbiol. 35(2), 511-514 (1997).
143. Florescu DF, Hill LA, McCartan MA, Grant W. Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr. Transplant. 12(3), 372-375 (2008).
144. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368(9530), 124-129 (2006).
145. Ison MG, Michaels MG; AST Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S166-S172 (2009).
146. Englund JA. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol. Blood Marrow Transplant. 7(Suppl.), 2S-4S (2001).
147. Martin ST, Torabi MJ, Gabardi S. Influenza in solid organ transplant recipients. Ann. Pharmacother. 46(2), 255-264 (2012).
148. Ison MG. Respiratory viral infections in transplant recipients. Antivir. Ther. (Lond.) 12(4 Pt B), 627-638 (2007).
149. Stucchi RS, Boin IF, Angerami RN et al. Correlations between A/H1N1 influenza and acute cellular rejection in liver transplantation patients. Transplant. Proc. 42(10), 4184-4186 (2010).
150. Krunic N, Yager TD, Himsworth D, Merante F, Yaghoubian S, Janeczko R. xTAG RVP assay: analytical and clinical performance. J. Clin. Virol. 40(Suppl. 1), S39-S46 (2007).
151. Kuypers J, Wright N, Ferrenberg J et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J. Clin. Microbiol. 44(7), 2382-2388 (2006).
152. Kumar D, Michaels MG, Morris MI et al.; American Society of Transplantation H1N1 Collaborative Study Group. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis. 10(8), 521-526 (2010).
153. Lee I, Barton TD. Viral respiratory tract infections in transplant patients: epidemiology, recognition and management. Drugs 67(10), 1411-1427 (2007).
154. Gangappa S, Kokko KE, Carlson LM et al. Immune responsiveness and protective immunity after transplantation. Transpl. Int. 21(4), 293-303 (2008).
155. Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J. Heart Lung Transplant. 27(3), 282-288 (2008).
156. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr. Opin. Infect. Dis. 24(4), 333-343 (2011).
157. Apalsch AM, Green M, Ledesma-Medina J, Nour B, Wald ER. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin. Infect. Dis. 20(2), 394-399 (1995).
158. Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin. Respir. Crit. Care Med. 28(2), 222-242 (2007).
159. Michaels MG, Fonseca-Aten M, Green M et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr. Transplant. 13(4), 451-456 (2009).
160. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am. J. Transplant. 3(2), 116-120 (2003).
161. Keck M, Mindru C, Kalil AC, Mercer DF, Florescu DF. Respiratory syncytial virus lower respiratory tract infection in a pediatric liver transplant recipient treated with oral ribavirin. Pediatr. Transplant. 16(8), E348-E351 (2012).
162. Pelaez A, Lyon GM, Force SD et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J. Heart Lung Transplant. 28(1), 67-71 (2009).